PT  - JOURNAL ARTICLE
AU  - Keshi, Lu
AU  - Weiwei, Xiao
AU  - Shoulin, Li
AU  - Xiaodong, Liu
AU  - Hao, Wang
AU  - Junhai, Jiang
AU  - Xiangwei, Wang
AU  - Rui, Wang
AU  - Pei, Zhu
TI  - Analysis of drug resistance of extended-spectrum beta-lactamases-producing <em>Escherichia coli</em> and <em>Klebsiella pneumoniae</em> in children with urinary tract infection
AID  - 10.15537/smj.2019.11.24547
DP  - 2019 Nov 01
TA  - Saudi Medical Journal
PG  - 1111--1115
VI  - 40
IP  - 11
4099  - http://smj.org.sa/content/40/11/1111.short
4100  - http://smj.org.sa/content/40/11/1111.full
SO  - Saudi Med J2019 Nov 01; 40
AB  - Objectives: To investigate the drug resistance of extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli (E. coli) and Klebsiella pneumoniae (K.pneumoniae) in children with urinary tract infection (UTI) and to provide the rationale for clinical use of antibiotics.Methods: This is a retrospective analysis of drug susceptibility in children with E. coli or K. pneumoniae-positive urine culture between August 2013 and August 2017, Shenzhen Children’s Hospital, Shenzhen, China. Drug resistance was statistically assessed using Fisher exact test and χ2 test.Results: A total of 698 cases of E. coli, 426 of which were confirmed ESBL-producing strains, and 217 cases of K. pneumoniae, including 111 ESBL-producing strains, were detected, and the difference in proportion of positive ESBL-producing strains (61.03% versus 51.15%) was statistically significant (p=0.010). The average drug resistance rates of E. coli and K. pneumoniae to piperacillin/tazobactam, meropenem, ertapenem, imipenem, and amikacin were <15%. The average resistance rates of ESBL-producing E. coli and K. pneumoniae to cefpodoxime, cefixime, cefazolin, and ceftriaxone was >98%, while average resistance rates for non-ESBL-producing bacteria to the above 4 drugs was <20%.Conclusion: In southern China, the proportion of ESBL-producing strains and the drug resistance rates of E. coli and K. pneumoniae in UTI in children was high, but their resistance rates to carbapenems and β-lactamase inhibitor complexes containing tazobactam were low. Carbapenems are the most effective antibacterial drugs for the treatment of ESBL-producing bacteria.